Slide 1: Accelerating Medicines: 4Q 2020 and FY 2020 Financial Results
Accelerating Medicines 4Q 2020 and FY 2020 Financial Results March 4, 2021
Slide 2: Disclaimer
Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. Trademarks and Service Marks The Certara design logo, “Certara,” and our o
Slide 3: Certara at a Glance: A Global Leader in Biosimulation
Certara at a Glance: A Global Leader in Biosimulation Business End-to-End Platform Customers 2020 Financials Software • Biosimulation 1,650+ $243.5mm 20+ Year 2020 Revenue Customers across History of innovation • Regulatory Submissions • Value Communication 61 countries 17% YoY Growth Tech-Enabled S
Slide 4: 4Q & FY 2020 Highlights
4Q & FY 2020 Highlights • Revenue was $64.6mm in 4Q 2020, and $243.5mm in 2020 • Year-over-year growth of 20% and 17% Key Financials Three Months Ended Year Ended • Reported net loss was ($54.4)mm in 4Q20, and ($49.4)mm in December 31, December 31, 2020 2019 2020 2019 2020 (in millions, except per s
Slide 5: 4Q and FY Results - Revenue
4Q and FY Results - Revenue Fourth Quarter GAAP Reported Revenue Full Year GAAP Reported Revenue ($Millions) ($Millions) 47.1 170.1 37.0 140.2 16.9 17.5 68.3 73.5 4Q 2019 4Q 2020 2019 2020 Software Services Software Services The Certara team remained focused on execution in 2020, delivering strong r
Slide 6: 4Q and FY Results - Net Bookings
4Q and FY Results - Net Bookings Fourth Quarter Reported Net Bookings Full Year Reported Net Bookings ($Millions) ($Millions) 215.0 63.3 191.9 48.0 21.7 21.0 67.6 73.3 4Q 2019 4Q 2020 2019 2020 (1) Software Services Software Services(1) Bookings are highly correlated with revenue and drive strong vi
Slide 7: 4Q and FY Results – Adjusted EBITDA
4Q and FY Results – Adjusted EBITDA ($Millions) Fourth Quarter Adjusted EBITDA(1) Full Year Adjusted EBITDA(1) ($Millions) ($Millions) 22.2 87.9 16.3 68.4 4Q 2019 4Q 2020 2019 2020 Adjusted EBITDA 30% 34% Margin(1) 33% 36% Certara’s level of profitability improved on a year-over-year basis (1) See A
Slide 8: Annual Expansion of Customer Partnerships
Annual Expansion of Customer Partnerships Our Customer Growth Strategy Land & Expand Cross-Sell Grow Deeper % of Top 300 Customers Purchasing Customers with ACV > $100,000 Customers with ACV > $1M 2+ Solutions 72% 261 67% 53 228 44 2019 2020 2019 2020 2019 2020 © Copyright 2020 Certara, L.P. All rig
Slide 9: FY 2020 – New Product or Product Updates
FY 2020 – New Product or Product Updates Certara announced 6 new products or product updates during 2020 • Developed QSP platform for COVID-19 vaccine – tests vaccine candidates across multiple patient populations • Launched version 3.0 of Immunogenicity (IG) QSP Simulator – integrates diverse input
Slide 10: FY 2021 Financial Guidance
FY 2021 Financial Guidance This financial guidance was provided as of March 4, 2021, and its inclusion in this presentation should not be construed as continued affirmation of such guidance beyond that date. • Certara expects full year 2021 revenue to be in the range Full Year 2021 of $272mm to $285
Slide 11: Appendix
Accelerating Medicines Appendix
Slide 12: Reconciliation of Net Income (Loss) to Adjusted EBITDA
Reconciliation of Net Income (Loss) to Adjusted EBITDA THREE MONTHS ENDED DECEMBER 31, YEAR ENDED DECEMBER 31, (in thousands) 2020 2019 2020 2019 Net loss attributable to common stockholders of Certara, Inc. ($54,447) ($6,015) ($49,397) ($8,926) Reconciliation to Adjusted EBITDA: Interest expense(a)
Slide 13: Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)
Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) THREE MONTHS ENDED DECEMBER 31, YEAR ENDED DECEMBER 31, (in thousands, except per share data) 2020 2019 2020 2019 Net loss attributable to common stockholders of Certara, Inc. ($54,447) ($6,015) ($49,397) ($8,926) Reconciliation to Ad
Slide 14: Reconciliation of Diluted EPS to Adjusted Diluted EPS
Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share THREE MONTHS ENDED DECEMBER 31, YEAR ENDED DECEMBER 31, 2020 2019 2020 2019 Diluted earnings per share ($0.40) ($0.05) ($0.37) ($0.07) Currency gain (a) 0.01 - 0.01 - Equity-based compensation expense(b) 0.46 0.01 0.
Slide 15: Notes to Adjusted EBITDA Reconciliation
Notes to Adjusted EBITDA Reconciliation (a) Represents amounts as determined under GAAP. (b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of o